KT-US-472-0141: Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication
- Title
- Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication
- Principal Investigator
- Safi, Salah Ud Din
- Phase
- NA
- Age Group
- Adult
- Applicable Disease Sites
- Leukemia
- Lymphoma
- Multiple Myeloma
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Crystal Peck, RN
- BMT Coordinator
- Phone: +1 304-598-4500
- Email: peckc@wvumedicine.org